Alkahest, Inc.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Methods of Inducing Liver Regeneration by Administering a Plasma Protein Fraction (US 11,660,316) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 23, 2027The maintenance fee for Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products (US 10,357,513) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders (US 10,525,107) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 2 fees due Oct 9 to 16, 2027 · next Oct 9
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,742,115 | Co-Crystals and Salts of CCR3-INHIBITORS In force · High confidence | In force | High confidence | |
| US 9,662,339 | Benzodioxane Inhibitors of Leukotriene Production for Combination Therapy In force · High confidence | In force | High confidence | |
| US 8,680,280 | Process for the Manufacturing of CRR Inhibitors In force · High confidence | In force | High confidence | |
| US 11,612,596 | Pharmaceutical Formulations Comprising CCR3 Antagonists In force · Medium confidence | In force | Medium confidence | |
| US 10,213,421 | Pharmaceutical Formulations Comprising CCR3 Antagonists In force · High confidence | In force | High confidence | |
| US 10,245,285 | Blood plasma and plasma fractions as therapy for tumor growth and progression In force · From the USPTO record | In force | From the USPTO record | |
| US 10,525,107 | Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders In force · High confidence | In force | High confidence | |
| US 12,697,373 | Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders In force · Low confidence | In force | Low confidence | |
| US 10,905,717 | Blood plasma and plasma fractions as therapy for tumor growth and progression In force · From the USPTO record | In force | From the USPTO record | |
| US 11,382,907 | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 28: 6 patents in force now held by others · 3 lapsed for an unpaid fee · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 10 abandoned · 7 no status recorded